Source link : https://newshealth.biz/health-news/concurrent-durvalumab-shows-no-survival-benefit-in-nsclc/
Phase 3 trial finds adding durvalumab during chemoradiation does not improve overall survival compared with standard consolidation therapy alone. Medscape Medical News Source link : https://www.medscape.com/viewarticle/concurrent-durvalumab-shows-no-survival-benefit-nsclc-2025a1000nxs?src=rss Author : Publish date : 2025-09-10 14:17:00 Copyright for syndicated content belongs to the linked Source.
The post Concurrent Durvalumab Shows No Survival Benefit in NSCLC first appeared on News Health.
—-
Author : News Health
Publish date : 2025-09-10 14:17:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8